Bone densitometry firm CompuMed's big plans for its OsteoGram bone mineral density testing technology may have hit a snag with the announcement that it has reacquired exclusive worldwide rights from the Bone Measurement Institute (BMI), a non-profit
Bone densitometry firm CompuMed's big plans for its OsteoGram bone mineral density testing technology may have hit a snag with the announcement that it has reacquired exclusive worldwide rights from the Bone Measurement Institute (BMI), a non-profit Merck subsidiary that had licensed the technology in 1995 (SCAN 9/13/95). Manhattan Beach, CA-based CompuMed reported that the OsteoGram Analysis Center generated a disappointingly small stream of royalty income.
BMI will return the rights to the OsteoGram technology at no cost to CompuMed, and will discontinue operating the OsteoGram Analysis Center on February 28, according to CompuMed. The company is considering distribution options such as new licensing revenues, as well as worldwide marketing of OsteoGram.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.